| 807- | GAR, | Garcinol inhibits cell proliferation and promotes apoptosis in pancreatic adenocarcinoma cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 |
| 806- | GAR, | Garcinol exerts anti-cancer effect in human cervical cancer cells through upregulation of T-cadherin |
| - | vitro+vivo, | Pca, | HeLa | - | vitro+vivo, | Cerv, | SiHa |
| 805- | GAR, | Cisplatin, | PacT, | Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumor Cells |
| - | Review, | NA, | NA |
| 804- | GAR, | Garcinol inhibits the proliferation of endometrial cancer cells by inducing cell cycle arrest |
| - | in-vitro, | EC, | HEC1B | - | in-vitro, | EC, | ISH |
| 803- | GAR, | Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
| 802- | GAR, | Garcinol acts as an antineoplastic agent in human gastric cancer by inhibiting the PI3K/AKT signaling pathway |
| - | in-vitro, | GC, | HGC27 |
| 801- | GAR, | Cisplatin, | Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers |
| - | in-vivo, | HNSCC, | NA |
| 800- | GAR, | Garcinol Regulates EMT and Wnt Signaling Pathways In Vitro and In Vivo, Leading to Anticancer Activity against Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | NA, | NA |
| 799- | GAR, | Apoptosis-inducing effect of garcinol is mediated by NF-kappaB signaling in breast cancer cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | NMSC, | MCF10 |
| 798- | GAR, | Garcinol, an acetyltransferase inhibitor, suppresses proliferation of breast cancer cell line MCF-7 promoted by 17β-estradiol |
| - | in-vitro, | BC, | MCF7 |
| 812- | GAR, | Anti-proliferative and anti-invasive effects of garcinol from Garcinia indica on gallbladder carcinoma cells |
| - | in-vitro, | Gall, | GBC-SD | - | in-vitro, | Gall, | NOZ |
| 813- | GAR, | GEM, | Dietary Garcinol Arrests Pancreatic Cancer in p53 and K-ras Conditional Mutant Mouse Model |
| - | in-vivo, | PC, | NA |
| 814- | GAR, | PacT, | Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-κB/Twist1 signaling pathways in a mouse 4T1 breast tumor model |
| - | in-vivo, | BC, | NA |
| 815- | GAR, | Garcinol from Garcinia indica Downregulates Cancer Stem-like Cell Biomarker ALDH1A1 in Nonsmall Cell Lung Cancer A549 Cells through DDIT3 Activation |
| - | vitro+vivo, | Lung, | A549 |
| 816- | GAR, | Garcinol downregulates Notch1 signaling via modulating miR-200c and suppresses oncogenic properties of PANC-1 cancer stem-like cells |
| - | in-vitro, | PC, | PANC1 |
| 817- | GAR, | Garcinol inhibits esophageal cancer metastasis by suppressing the p300 and TGF-β1 signaling pathways |
| - | vitro+vivo, | SCC, | KYSE150 | - | vitro+vivo, | SCC, | KYSE450 |
| 818- | GAR, | GB, | Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs |
| - | in-vitro, | Lung, | A549 |
| 819- | GAR, | Enhanced Hsa-miR-181d/p-STAT3 and Hsa-miR-181d/p-STAT5A Ratios Mediate the Anticancer Effect of Garcinol in STAT3/5A-Addicted Glioblastoma |
| - | in-vivo, | GBM, | U87MG | - | in-vitro, | GBM, | GBM |
| 820- | GAR, | Garcinol in gastrointestinal cancer prevention: recent advances and future prospects |
| - | Review, | NA, | NA |
| 821- | GAR, | Garcinol inhibits cell growth in hepatocellular carcinoma Hep3B cells through induction of ROS-dependent apoptosis |
| - | in-vitro, | Liver, | Hep3B |
| 822- | GAR, | Garcinol, a Polyisoprenylated Benzophenone Modulates Multiple Proinflammatory Signaling Cascades Leading to the Suppression of Growth and Survival of Head and Neck Carcinoma |
| - | vitro+vivo, | HNSCC, | NA |
| 823- | GAR, | Garcinol Potentiates TRAIL-Induced Apoptosis through Modulation of Death Receptors and Antiapoptotic Proteins |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF10 | - | in-vitro, | CRC, | HCT116 |
| 824- | GAR, | Garcinol A Novel Inhibitor of Platelet Activation and Apoptosis |
| - | in-vitro, | NA, | NA |
| 825- | GAR, | Garcinol-induced apoptosis in prostate and pancreatic cancer cells is mediated by NF- kappaB signaling |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | Bxpc-3 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | C4-2B |
| 796- | GAR, | Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression |
| - | vitro+vivo, | Pca, | HeLa |
| 832- | GAR, | Rad, | Garcinol, a Histone Acetyltransferase Inhibitor, Radiosensitizes Cancer Cells by Inhibiting Non-Homologous End Joining |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | NA, | HeLa |
| 831- | GAR, | CUR, | Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells |
| - | in-vitro, | AML, | HL-60 |
| 830- | GAR, | Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and Akt survival signaling in human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 829- | GAR, | The Role of T-Cadherin (CDH13) in Treatment Options with Garcinol in Melanoma |
| - | vitro+vivo, | Melanoma, | NA |
| 828- | GAR, | Cisplatin, | Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells |
| - | in-vitro, | Ovarian, | OVCAR-3 |
| 827- | GAR, | Garcinol Is an HDAC11 Inhibitor |
| - | in-vitro, | NA, | NA |
| 826- | GAR, | Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo |
| - | vitro+vivo, | HCC, | HepG2 | - | vitro+vivo, | Liver, | HUH7 |
| 793- | GAR, | Garcinol inhibits tumour cell proliferation, angiogenesis, cell cycle progression and induces apoptosis via NF-κB inhibition in oral cancer |
| - | in-vitro, | SCC, | SCC9 | - | in-vitro, | SCC, | SCC4 | - | in-vitro, | SCC, | SCC25 |
| 794- | GAR, | Garcinol Enhances TRAIL-Induced Apoptotic Cell Death through Up-Regulation of DR5 and Down-Regulation of c-FLIP Expression |
| - | in-vitro, | RCC, | NA | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | NA |
| 795- | GAR, | Garcinol—A Natural Histone Acetyltransferase Inhibitor and New Anti-Cancer Epigenetic Drug |
| - | Review, | NA, | NA |
| 797- | GAR, | CUR, | Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | OS, | U2OS | - | in-vitro, | OS, | SaOS2 |
| 1187- | GAs, | Ginkgolic Acid C 17:1, Derived from Ginkgo biloba Leaves, Suppresses Constitutive and Inducible STAT3 Activation through Induction of PTEN and SHP-1 Tyrosine Phosphatase |
| - | in-vitro, | Melanoma, | U251 | - | in-vitro, | Melanoma, | MM.1S |
| 1186- | GAs, | Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis |
| - | in-vitro, | PC, | NA | - | in-vitro, | Nor, | HUVECs | - | in-vivo, | PC, | NA |
| 7213- | GAs, | Anti-Cancer Properties of Ginkgolic Acids in Human Nasopharyngeal Carcinoma CNE-2Z Cells via Inhibition of Heat Shock Protein 90 |
| - | vitro+vivo, | NPC, | CNE2 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Lung, | H1975 |
| 7204- | GAs, | The Pharmacology and Toxicology of Ginkgolic Acids: Secondary Metabolites from Ginkgo biloba |
| - | Review, | Nor, | NA |
| 7214- | GAs, | Ginkgolic Acid Suppresses Nasopharyngeal Carcinoma Growth by Inducing Apoptosis and Inhibiting AKT/NF-κB Signaling |
| - | vitro+vivo, | NPC, | CNE2 |
| 7224- | GAs, | Ginkgolic acids inhibit migration in breast cancer cells by inhibition of NEMO sumoylation and NF-κB activity |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 7227- | GAs, | Review of Ginkgo biloba-induced toxicity, from experimental studies to human case reports |
| - | Review, | Nor, | NA |
| 7233- | GAs, | Antitumor effects of ginkgolic acid in human cancer cell occur via cell cycle arrest and decrease the Bcl-2/Bax ratio to induce apoptosis |
| - | in-vitro, | Laryn, | HEp2 |
| - | in-vitro, | Nor, | RAW264.7 |
| 7216- | GBE, | Cytotoxic effect of Ginkgo biloba kernel extract on HCT116 and A2058 cancer cell lines |
| - | in-vitro, | Melanoma, | A2058 | - | in-vitro, | CRC, | HCT116 |
| - | vitro+vivo, | NSCLC, | NA |
| 7226- | GBE, | Ginkgo biloba exocarp extracts induces apoptosis in Lewis lung cancer cells involving MAPK signaling pathways |
| - | vitro+vivo, | Lung, | NA |
| 7223- | GBE, | Ginkgo biloba Exocarp Extract Inhibits the Metastasis of B16-F10 Melanoma Involving PI3K/Akt/NF- κ B/MMP-9 Signaling Pathway |
| - | vitro+vivo, | Melanoma, | B16-F10 |
| 7234- | GBE, | Ginkgo Biloba Extract Ameliorates Oxidative Phosphorylation Performance and Rescues Aβ-Induced Failure |
| - | in-vitro, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid